ClinicalTrials.gg
Active, not recruitingNCT05726227STEP YoungUpdated Oct 7, 2026

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

A Phase 3 interventional study of Semaglutide and Placebo in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 56 sites in 10 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Updated Oct 7, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
35th of 143
212 · median 100
Started
2023
with 14 others
Phase 3
42 of 143
10 open now
Primary completion
2025-10
later than 4 of 76 live
Registered
59th of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 35th largest by enrollment, is one of 15 that started in 2023, is one of 42 in phase 3, reaches primary completion later than 4 of the 76 other live ones, and was the 59th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dummy" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults.

The child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of parent(s) or legally acceptable representative (LAR) of participant and child assent, as age-appropriate, obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. a) The parents or LAR of the child must sign and date the Informed Consent Form (according to local requirements) b) The child must sign and date the Child Assent Form or provide oral assent (according to local requirements)
  • Age at the time of signing informed consent. a)Group Kids: 6 to less than 12 years. b) Group Teens: 12 to less than 18 years and Tanner stage greater than 1
  • (BMI), at screening and randomisation, corresponding to a) Group Kids: greater than or equal to 95th percentile. b) Group Teens: greater than or equal to 95th percentile or greater than or equal to 85th percentile with the presence of at least 1 weight-related comorbidity (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes mellitus (T2D)
  • History of at least one unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification programme (diet and exercise counselling) for at least 3 months
  • Body weight of greater than 45 kilogram (kg) at screening and randomisation
  • For participants with T2D at screening, the following additional criterion applies: (HbA1c) less than or equal to 10.0 percent (86 millimoles per mole [mmol/mol]) as measured by central laboratory at screening

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening
  • Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed: a) liposuction and/or abdominoplasty, if performed greater than 1 year prior to screening. b) adjustable gastric banding, if the band has been removed greater than 1 year prior to screening. c) intragastric balloon, if the balloon has been removed greater than 1 year prior to screening. d)duodenal-jejunal bypass liner (e.g., nonbarrier), if the sleeve has been removed greater than 1 year prior to screening
  • Type 1 diabetes mellitus or monogenic diabetes
  • Participants with endocrine, hypothalamic, or syndromic obesity
  • For participants with T2D at screening, the following additional key criterion applies: Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
212 participants (actual)

Study arms

  • Experimental
    Group Kids

    Participants in the age group 6 to less than (\<) 12 years will receive once weekly subcutaneous (s.c.) injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Semaglutide · Drug: Placebo

  • Experimental
    Group Teens

    Participants in the age group 12 to \< 18 years will receive once weekly s.c. injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Semaglutide · Drug: Placebo

Interventions

  • Semaglutide will be administered subcutaneously once weekly.

  • DrugPlacebo

    Placebo will be administered subcutaneously once-weekly.

06

What researchers measure

Primary outcomes

  1. Group Kids: Change in body mass index (BMI)

    Measured in percentage (%)

    Time frame: From baseline (week 0) to week 68

Secondary outcomes

  1. Group Kids: Improvement in weight category

    Measured as count of participants. Weight categories based on growth charts from Center for Disease Control (CDC).gov: Normal weight= BMI less than (\<) 85th percentile, Overweight= BMI greater than or equal to (\>=) 85th - \<95th percentile, Obesity class I= BMI \>=95th - \<120% of the 95th percentile, Obesity class II= BMI \>=120% - \<140% of the 95th percentile, Obesity class III= BMI \>=140% of the 95th percentile.

    Time frame: From baseline (week 0) to week 68

  2. Group Teens: Change in BMI

    Measured in %

    Time frame: From week 0 to week 68

  3. Group Kids and Group Teens: Change in BMI

    Measured in %

    Time frame: From week 0 to week 104

  4. Group Teens: Improvement in weight category

    Measured as count of participants. Weight categories based on growth charts from CDC.gov: Normal weight= BMI less than (\<) 85th percentile, Overweight= BMI greater than or equal to (\>=) 85th - \<95th percentile, Obesity class I= BMI \>=95th - \<120% of the 95th percentile, Obesity class II= BMI \>=120% - \<140% of the 95th percentile, Obesity class III= BMI \>=140% of the 95th percentile.

    Time frame: From week 0 to week 68

  5. Group Kids and Group Teens: Improvement in weight category

    Measured as count of participants. Weight categories based on growth charts from CDC.gov: Normal weight= BMI less than (\<) 85th percentile, Overweight= BMI greater than or equal to (\>=) 85th - \<95th percentile, Obesity class I= BMI \>=95th - \<120% of the 95th percentile, Obesity class II= BMI \>=120% - \<140% of the 95th percentile, Obesity class III= BMI \>=140% of the 95th percentile.

    Time frame: From week 0 to week 104

  6. Group Kids and Group Teens: Change in body weight

    Measured in percentage

    Time frame: From week 0 to week 68

  7. Group Kids and Group Teens: Change in body weight

    Measured in percentage

    Time frame: From week 0 to week 104

  8. Group Kids and Group Teens: Change in body weight

    Measured in kilograms (kg)

    Time frame: From week 0 to week 68

  9. Group Kids and Group Teens: Change in body weight

    Measured in kilograms (kg)

    Time frame: From week 0 to week 104

  10. Group Kids and Group Teens: Change in BMI percentage of the 95th percentile

    Measured in percentage points

    Time frame: From week 0 to week 68

  11. Group Kids and Group Teens: Change in BMI percentage of the 95th percentile

    Measured in percentage points

    Time frame: From week 0 to week 104

  12. Group Kids and Group Teens: Change in BMI Standard deviation score (SDS)

    Measured as score on a scale. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a Z (SDS) score was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction.

    Time frame: From week 0 to week 68

  13. Group Kids and Group Teens: Change in BMI SDS

    Measured as score in a scale. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a Z (SDS) score was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction.

    Time frame: From week 0 to week 104

  14. Group Kids and Group Teens: Change in waist circumference

    Measured in centimeters (cm)

    Time frame: From week 0 to week 68

  15. Group Kids and Group Teens: Change in waist circumference

    Measured in centimeters (cm)

    Time frame: From week 0 to week 104

  16. Group Kids and Group Teens: Change in systolic blood pressure

    Measured in millimeters of mercury (mmHg)

    Time frame: From week 0 to week 68

  17. Group Kids and Group Teens: Change in systolic blood pressure

    Measured in millimeters of mercury (mmHg)

    Time frame: From week 0 to week 104

  18. Group Kids and Group Teens: Change in diastolic blood pressure

    Measured in mmHg

    Time frame: From week 0 to week 68

  19. Group Kids and Group Teens: Change in diastolic blood pressure

    Measured in mmHg

    Time frame: From week 0 to week 104

  20. Group Kids and Group Teens: Change in total cholesterol

    Measured in %

    Time frame: From week 0 to week 68

  21. Group Kids and Group Teens: Change in total cholesterol

    Measured in %

    Time frame: From week 0 to week 104

  22. Group Kids and Group Teens: Change in high density lipoprotein (HDL)

    Measured in %

    Time frame: From week 0 to week 68

  23. Group Kids and Group Teens: Change in high density lipoprotein (HDL)

    Measured in %

    Time frame: From week 0 to week 104

  24. Group Kids and Group Teens: Change in low density lipoprotein (LDL)

    Measured in %

    Time frame: From week 0 to week 68

  25. Group Kids and Group Teens: Change in low density lipoprotein (LDL)

    Measured in %

    Time frame: From week 0 to week 104

  26. Group Kids and Group Teens: Change in very low density lipoprotein (VLDL)

    Measured in %

    Time frame: From week 0 to week 68

  27. Group Kids and Group Teens: Change in very low density lipoprotein (VLDL)

    Measured in %

    Time frame: From week 0 to week 104

  28. Group Kids and Group Teens: Change in triglycerides

    Measured in %

    Time frame: From week 0 to week 68

  29. Group Kids and Group Teens: Change in triglycerides

    Measured in %

    Time frame: From week 0 to week 104

  30. Group Kids and Group Teens: Change in high sensitivity C-reactive protein (hs-CRP)

    Measured in %

    Time frame: From week 0 to week 68

  31. Group Kids and Group Teens: Change in high sensitivity C-reactive protein (hs-CRP)

    Measured in %

    Time frame: From week 0 to week 104

  32. Group Kids and Group Teens: Change in glycated haemoglobin (HbA1c)

    Measured in % point

    Time frame: From week 0 to week 68

  33. Group Kids and Group Teens: Change in glycated haemoglobin (HbA1c)

    Measured in % point

    Time frame: From week 0 to week 104

  34. Group Kids and Group Teens: Change in fasting plasma glucose

    Measured in millimoles per liter (mmol/L)

    Time frame: From week 0 to week 68

  35. Group Kids and Group Teens: Change in fasting plasma glucose

    Measured in millimoles per liter (mmol/L)

    Time frame: From week 0 to week 104

  36. Group Kids and Group Teens: Change in fasting plasma glucose

    Measured in milligrams per deciliter (mg/dL)

    Time frame: From week 0 to week 68

  37. Group Kids and Group Teens: Change in fasting plasma glucose

    Measured in milligrams per deciliter (mg/dL)

    Time frame: From week 0 to week 104

  38. Group Kids and Group Teens: Change in fasting insulin

    Measured in %

    Time frame: From week 0 to week 68

  39. Group Kids and Group Teens: Change in fasting insulin

    Measured in %

    Time frame: From week 0 to week 104

  40. Group Kids and Group Teens: Change in alanine transaminase (ALT)

    Measured in milliunits per liter (mU/L)

    Time frame: From week 0 to week 68

  41. Group Kids and Group Teens: Change in alanine transaminase (ALT)

    Measured in milliunits per liter (mU/L)

    Time frame: From week 0 to week 104

  42. Group Kids and Group Teens: Change in total fat mass, by Dual energy X-ray absorptiometry (DXA) relative to total body mass

    Measured in % points

    Time frame: From week 0 to week 68

  43. Group Kids and Group Teens: Change in total fat mass, by Dual energy X-ray absorptiometry (DXA) relative to total body mass

    Measured in % points

    Time frame: From week 0 to week 104

  44. Group Kids and Group Teens: Change in lean body mass, by DXA relative to total body mass

    Measured in % points

    Time frame: From week 0 to week 68

  45. Group Kids and Group Teens: Change in lean body mass, by DXA relative to total body mass

    Measured in % points

    Time frame: From week 0 to week 104

  46. Group Kids and Group Teens: Relative change in visceral fat mass by DXA

    Measured in %

    Time frame: From week 0 to week 68

  47. Group Kids and Group Teens: Relative change in visceral fat mass by DXA

    Measured in %

    Time frame: From week 0 to week 104

  48. Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 5% reduction of BMI (yes/no)

    Measured in count of participants

    Time frame: From week 0 to week 68

  49. Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 5% reduction of BMI (yes/no)

    Measured in count of participants

    Time frame: From week 0 to week 104

  50. Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 10% reduction of BMI (yes/no)

    Measured in count of participants

    Time frame: From week 0 to week 68

  51. Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 10% reduction of BMI (yes/no)

    Measured in count of participants

    Time frame: From week 0 to week 104

  52. Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 15% reduction of BMI (yes/no)

    Measured in count of participants

    Time frame: From week 0 to week 68

  53. Group Kids and Group Teens: Number of participants achieving greater than or equal to (>=) 15% reduction of BMI (yes/no)

    Measured in count of participants

    Time frame: From week 0 to week 104

  54. Group Kids and Group Teens: Number of treatment emergent adverse events (AEs)

    Measured as count of events

    Time frame: From week 0 to week 68

  55. Group Kids and Group Teens: Number of treatment emergent adverse events (AEs)

    Measured as count of events

    Time frame: From week 0 to week 111

  56. Group Kids and Group Teens: Number of treatment emergent serious adverse events (SAEs)

    Measured as count of events

    Time frame: From week 0 to week 68

  57. Group Kids and Group Teens: Number of treatment emergent serious adverse events (SAEs)

    Measured as count of events

    Time frame: From week 0 to week 111

  58. Group Kids and Group Teens: Change in pulse

    Measured as beats per minute

    Time frame: From week 0 to week 68

  59. Group Kids and Group Teens: Change in pulse

    Measured as beats per minute

    Time frame: From week 0 to week 104

  60. Group Kids and Group Teens: Change in amylase

    Measured as units per liter (U/L)

    Time frame: From week 0 to week 68

  61. Group Kids and Group Teens: Change in amylase

    Measured as units per liter (U/L)

    Time frame: From week 0 to week 104

  62. Group Kids and Group Teens: Change in lipase

    Measured as U/L

    Time frame: From week 0 to week 68

  63. Group Kids and Group Teens: Change in lipase

    Measured as U/L

    Time frame: From week 0 to week 104

  64. Group Kids and Group Teens: Change in calcitonin

    Measured as nanograms per liter (ng/L)

    Time frame: From week 0 to week 68

  65. Group Kids and Group Teens: Change in calcitonin

    Measured as nanograms per liter (ng/L)

    Time frame: From week 0 to week 104

  66. Group Kids and Group Teens: Change in bone mineral density, by DXA

    Measured as grams per square centimeter (g/cm\^2)

    Time frame: From week 0 to week 68

  67. Group Kids and Group Teens: Change in bone mineral density, by DXA

    Measured as grams per square centimeter (g/cm\^2)

    Time frame: From week 0 to week 104

  68. Group Kids and Group Teens: Number of treatment emergent hypoglycaemic episodes (for T2D only)

    Measured as count of episodes

    Time frame: From week 0 to week 68

  69. Group Kids and Group Teens: Number of treatment emergent hypoglycaemic episodes (for T2D only)

    Measured as count of episodes

    Time frame: From week 0 to week 111

07

Study locations

56 sites
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Oct 2025, 27 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 27 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2023
First posted
Feb 13, 2023
StartActual
Jul 7, 2023
Primary completionActual
Oct 15, 2025
CompletionEst.
Dec 7, 2026
Results delay requested
Oct 6, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
210 (estimated)→212 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Enrollment 210 (estimated)→212 (actual)
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05726227
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 13, 2023
Start date
Jul 7, 2023
Primary completion
Oct 15, 2025
Completion
Dec 7, 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion